Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|December 2, 2009

Life Sciences Logistics Provider Expands into China

The Life Sciences logistics solutions provider, Biocair has recently expanded its operations into China.  The opening ceremony, held on November 12th was attended by Carma Eliott, the British Consul General in Shanghai, who cut the ribbon together with Andy King, the Managing Director of Biocair. The British Consul general congratulated Biocair on the issue of their new Chinese Business Licence.  She re-affirmed the British Government’s support of the Life Sciences sector and acknowledged the vital logistics role for research materials and clinical trial samples that Biocair can now provide companies in China.

Biocair, established since 1987, is a proven international specialist in transporting temperature sensitive biological materials and drugs for clinical trials in and out of the main pharmaceutical and biopharmaceutical clusters in UK, Europe, USA, South America, Russia, Japan, and India.  The new logistics operation in Shanghai has extended their Asia service offering.  Andy King commented; “This expansion into China is a key step in our international business development plan in response to growing customer demand in the region”. He went on to say: “We really appreciated all the encouragement and support we have had from customers, which helped us make this investment decision to enter the China market.”

Biocair used the consultancy company Asiasetup to assist in setting up operations in China. Asiasetup was able to gain ‘Wholly Foreign Owned Enterprise’ approval at Municipal level in two weeks and Biocair’s business license was granted two weeks later.  


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.